Defibrotide Prevents the Activation of Macrovascular and Microvascular Endothelia Caused by Soluble Factors Released to Blood by Autologous Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 4, 2011, Pages 497-506

  Palomo, Marta ^a   Diaz Ricart, Maribel ^a   Rovira, Montserrat ^a   Escolar, Ginés ^a   Carreras, Enric ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Autologous HSCT; Defibrotide; Endothelial activation; HMEC 1; HUVEC

Indexed keywords

CELL RECEPTOR; DEFIBROTIDE; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; SCLEROPROTEIN; THROMBOPLASTIN; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD SMEAR; CELL ACTIVATION; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HUMAN CELL; MALE; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOSIS; VASCULAR ENDOTHELIUM;

ADULT; AGED; CELLS, CULTURED; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PLATELET AGGREGATION INHIBITORS; POLYDEOXYRIBONUCLEOTIDES; PROTO-ONCOGENE PROTEINS C-AKT; RETROSPECTIVE STUDIES; SERUM; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 79952615903     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.11.019     Document Type: Article

References (39)

1. Ljungman P., Bregni M., Brune M., et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010, 45:219-234.
2. Palomo M., Diaz-Ricart M., Carbo C., et al. The release of soluble factors contributing to endothelial activation and damage after hematopoietic stem cell transplantation is not limited to the allogeneic setting and involves several pathogenic mechanisms. Biol Blood Marrow Transplant 2009, 15:537-546.
3. Palomo M., Diaz-Ricart M., Carbo C., et al. Endothelial dysfunction after hematopoietic stem cell transplantation: role of the conditioning regimen and the type of transplantation. Biol Blood Marrow Transplant 2010, 16:985-993.
4. Aird W.C. Spatial and temporal dynamics of the endothelium. J Thromb Haemost 2005, 3:1392-1406.
5. Hunt B.J., Jurd K.M. Endothelial cell activation. A central pathophysiological process. BMJ 1998, 316:1328-1329.
6. Aird W.C. Endothelium in health and disease. Pharmacol Rep 2008, 60:139-143.
7. Richardson P.G., Murakami C., Jin Z., et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002, 100:4337-4343.
8. Ribatti D., Nico B., Vacca A., Roncali L., Dammacco F. Endothelial cell heterogeneity and organ specificity. J Hematother Stem Cell Res 2002, 11:81-90.
9. Eissner G., Kohlhuber F., Grell M., et al. Critical involvement of transmembrane tumor necrosis factor-alpha in endothelial programmed cell death mediated by ionizing radiation and bacterial endotoxin. Blood 1995, 86:4184-4193.
10. Eissner G., Multhoff G., Gerbitz A., et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide. Blood 2002, 100:334-340.
11. Kornblum N., Ayyanar K., Benimetskaya L., Richardson P., Iacobelli M., Stein C.A. Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action. Oligonucleotides 2006, 16:105-114.
12. Palmer K.J., Goa K.L. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs 1993, 45:259-294.
13. Chopra R., Eaton J.D., Grassi A., et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000, 111:1122-1129.
14. Richardson P.G., Soiffer R.J., Antin J.H., et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant 2010, 16:1005-1017.
15. Bracht F., Schror K. Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro. Biochem Biophys Res Commun 1994, 200:933-937.
16. Klocking H.P. Acute t-PA release by defibrotide. Thromb Res 1992, 66:779-785.
17. Ulutin O.N., Balkuv-Ulutin S., Bezer-Goker B., et al. Effect of defibrotide on platelet function. Semin Thromb Hemost 1996, 22(Suppl 1):21-24.
18. Zhou Q., Chu X., Ruan C. Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thromb Haemost 1994, 71:507-510.
19. Falanga A., Vignoli A., Marchetti M., Barbui T. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia 2003, 17:1636-1642.
20. Jaffe E.A., Nachman R.L., Becker C.G., Minick C.R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973, 52:2745-2756.
21. Serradell M., Diaz-Ricart M., Cases A., et al. Uremic medium disturbs the hemostatic balance of cultured human endothelial cells. Thromb Haemost 2001, 86:1099-1105.
22. Ades E.W., Candal F.J., Swerlick R.A., et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992, 99:683-690.
23. Koehl G.E., Geissler E.K., Iacobelli M., et al. Defibrotide: an endothelium protecting and stabilizing drug, has an anti-angiogenic potential in vitro and in vivo. Cancer Biol Ther 2007, 6:686-690.
24. De Mey J., Moeremans M., Geuens G., Nuydens R., De B.M. High resolution light and electron microscopic localization of tubulin with the IGS (immuno gold staining) method. Cell Biol Int Rep 1981, 5:889-899.
25. Scopsi L., Larsson L.I., Bastholm L., Nielsen M.H. Silver-enhanced colloidal gold probes as markers for scanning electron microscopy. Histochemistry 1986, 86:35-41.
26. Diaz-Ricart M., Tandon N.N., Gomez-Ortiz G., et al. Antibodies to CD36 (GPIV) inhibit platelet adhesion to subendothelial surfaces under flow conditions. Arterioscler Thromb Vasc Biol 1996, 16:883-888.
27. Muggli R., Baumgartner H.R., Tschopp T.B., Keller H. Automated microdensitometry and protein assays as a measure for platelet adhesion and aggregation on collagen-coated slides under controlled flow conditions. J Lab Clin Med 1980, 95:195-207.
28. Sakariassen K.S., Aarts P.A., de Groot P.G., Houdijk W.P., Sixma J.J. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components. J Lab Clin Med 1983, 102:522-535.
29. Fuste B., Diaz-Ricart M., Cases A., Lopez-Pedret J., Ordinas A., Escolar G. Erythropoietin does not modify the prothrombotic effect induced by uremic media on endothelial cells. Haematologica 2002, 87:1006-1008.
30. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979, 76:4350-4354.
31. DeLeve L.D., Wang X., Kanel G.C., et al. Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome. Hepatology 2003, 38:900-908.
32. Unger R.E., Krump-Konvalinkova V., Peters K., Kirkpatrick C.J. In vitro expression of the endothelial phenotype: comparative study of primary isolated cells and cell lines, including the novel cell line HPMEC-ST1.6R. Microvasc Res 2002, 64:384-397.
33. Cuenda A., Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007, 1773:1358-1375.
34. Dagia N.M., Agarwal G., Kamath D.V., et al. A preferential p110alpha/gamma PI3K inhibitor attenuates experimental inflammation by suppressing the production of proinflammatory mediators in a NF-kappaB-dependent manner. Am J Physiol Cell Physiol 2010, 298:C929-C941.
35. Spitzer T.R. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001, 27:893-898.
36. Bonnefoy A., Harsfalvi J., Pfliegler G., Fauvel-Lafeve F., Legrand C. The subendothelium of the HMEC-1 cell line supports thrombus formation in the absence of von Willebrand factor and collagen types I, III and VI. Thromb Haemost 2001, 85:552-559.
37. Ribeiro M.J., Phillips D.J., Benson J.M., Evatt B.L., Ades E.W., Hooper W.C. Hemostatic properties of the SV-40 transfected human microvascular endothelial cell line (HMEC-1). A representative in vitro model for microvascular endothelium. Thromb Res 1995, 79:153-161.
38. Pescador R., Porta R., Ferro L. An integrated view of the activities of defibrotide. Semin Thromb Hemost 1996, 22(Suppl 1):71-75.
39. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4:988-1004.